Insider Selling: Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Insider Sells 12,239 Shares of Stock

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) insider Greg Keenan sold 12,239 shares of the company’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $8.00, for a total value of $97,912.00. Following the sale, the insider now owns 161,789 shares in the company, valued at $1,294,312. The trade was a 7.03 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Aurinia Pharmaceuticals Stock Performance

Shares of Aurinia Pharmaceuticals stock traded up $0.10 on Tuesday, hitting $8.08. The stock had a trading volume of 3,640,172 shares, compared to its average volume of 1,449,999. Aurinia Pharmaceuticals Inc. has a twelve month low of $4.71 and a twelve month high of $10.67. The business’s 50 day moving average is $8.13 and its two-hundred day moving average is $7.85. The company has a quick ratio of 5.11, a current ratio of 5.60 and a debt-to-equity ratio of 0.17. The stock has a market cap of $1.16 billion, a price-to-earnings ratio of -53.86 and a beta of 1.22.

Hedge Funds Weigh In On Aurinia Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the company. Invesco Ltd. grew its position in Aurinia Pharmaceuticals by 1.0% during the fourth quarter. Invesco Ltd. now owns 144,112 shares of the biotechnology company’s stock worth $1,294,000 after buying an additional 1,421 shares in the last quarter. Bridgefront Capital LLC boosted its holdings in shares of Aurinia Pharmaceuticals by 12.9% in the 4th quarter. Bridgefront Capital LLC now owns 16,606 shares of the biotechnology company’s stock valued at $149,000 after purchasing an additional 1,891 shares in the last quarter. Cetera Investment Advisers boosted its holdings in shares of Aurinia Pharmaceuticals by 3.2% in the 4th quarter. Cetera Investment Advisers now owns 64,638 shares of the biotechnology company’s stock valued at $580,000 after purchasing an additional 2,000 shares in the last quarter. Teacher Retirement System of Texas lifted its stake in shares of Aurinia Pharmaceuticals by 5.9% in the 4th quarter. Teacher Retirement System of Texas now owns 36,098 shares of the biotechnology company’s stock valued at $324,000 after acquiring an additional 2,020 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its stake in shares of Aurinia Pharmaceuticals by 368.5% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 2,635 shares during the last quarter. Institutional investors and hedge funds own 36.83% of the company’s stock.

Wall Street Analyst Weigh In

Separately, StockNews.com lowered Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, February 19th.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.